Shares of Hologic (HOLX) Rally 1.17%

On a relative basis, the stock has outperformed the S&P 500 by 3.01% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.17% in the last 1 week, and is up 7.51% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 4.85% and the 50-Day Moving Average is 6.24%.

Hologic (NASDAQ:HOLX): The stock opened at $36.65 on Friday but the bulls could not build on the opening and the stock topped out at $36.93 for the day. The stock traded down to $36.31 during the day, due to lack of any buying support eventually closed down at $36.35 with a loss of -0.49% for the day. The stock had closed at $36.53 on the previous day. The total traded volume was 2,696,647 shares.


The company Insiders own 0.84% of Hologic shares according to the proxy statements. Institutional Investors own 91.83% of Hologic shares. In a related news, The Securities and Exchange Commission has divulged that Leaming Nancy, director of Hologic Inc, had unloaded 6,221 shares at an average price of $36.03 in a transaction dated on July 8, 2016. The total value of the transaction was worth $224,143.

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.